Fundz

enGene Appoints Erik T. Goluboff as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer

PUBLIC · ENGNNov 11, 2026

Position

Chief Medical Officer

Company

enGene

Erik T. Goluboff
CanadaBiotechnologyGeneticsTherapeuticsBiotechnology Research

Description

enGene Therapeutics Inc. announced the appointments of Erik T. Goluboff as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer

Quick answer

enGene Appoints Erik T. Goluboff as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer (November 11, 2026). enGene is based in Canada.

Who is the new Chief Medical Officer at enGene?
enGene named Erik T. Goluboff Chief Medical Officer, announced November 11, 2026.
What did enGene announce on November 11, 2026?
enGene Therapeutics Inc. announced the appointments of Erik T. Goluboff as Chief Medical Officer and Jason Duncan as Chief Legal and Administrative Officer
What does enGene do?
enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues.
Where is enGene based?
enGene is based in Canada.
Which similar companies made leadership changes around the same time?
Crispr Therapeutics (November 3, 2026), Genetix Biotherapeutics (October 19, 2026), BioMarin Pharmaceutical (October 5, 2026) and Nomad Power Solutions, Inc. (November 10, 2026) also announced leadership changes within 45 days of enGene.

Source: Fundz verified event record.

Other recent leadership changes in Genetics and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at enGene, and when

A new leader at enGene brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day enGene raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at enGene, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at enGene. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

enGene

Location

4868 Rue Levy, Suite 220

Canada

About

enGene Inc. is a biotechnology company developing a proprietary non-viral gene therapy platform for localized delivery of nucleic acid payloads to mucosal tissues. The dually derived chitosan (DDX) platform has a high-degree of payload flexibility including DNA and various forms of RNA (siRNA, shRNA, lncRNA etc.) with broad tissue and disease applications. In addition to developing EG-70 for BCG-unresponsive NMIBC, enGene is developing unique genetic medicines for respiratory indications. The company is also evolving its technology to enable applications in several mucosal tissues such as the nasal and genital mucosa as well as the gastrointestinal tract among others. enGene is supported financially by top-tier institutional investors including Forbion Capital Partners, Fonds de Solidarité FTQ, Pharmstandard International S.A., Lumira Capital and Johnson & Johnson Development Corporation.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment enGene changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Ryan
Likely contact at this company
••••••••@••••••••

See Ryan's verified email →

Joan
Likely contact at this company
••••••••@••••••••

See Joan's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for enGene's next move

Learn about Strategic plan

enGene changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.